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Abstract
Pseudomonas aeruginosa (P. aeruginosa) infections are associated with considerable morbidity and mortality in
immunocompromised patients due to antibiotic resistance. Therefore, we investigated the efficacy of the anti-P.
aeruginosa serotype O11 lipopolysaccharide monoclonal antibody Panobacumab in a clinically relevant murine
model of neutropenia induced by cyclophosphamide and in combination with meropenem in susceptible and
meropenem resistant P. aeruginosa induced pneumonia. We observed that P. aeruginosa induced pneumonia was
dramatically increased in neutropenic mice compared to immunocompetent mice. First, Panobacumab significantly
reduced lung inflammation and enhanced bacterial clearance from the lung of neutropenic host. Secondly,
combination of Panobacumab and meropenem had an additive effect. Third, Panobacumab retained activity on a
meropenem resistant P. aeruginosa strain. In conclusion, the present data established that Panobacumab
contributes to the clearance of P. aeruginosa in neutropenic hosts as well as in combination with antibiotics in
immunocompetent hosts. This suggests beneficial effects of co-treatment even in immunocompromised individuals,
suffering most of the morbidity and mortality of P. aeruginosa infections.
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Introduction
P. aeruginosa is a virulent pathogen leading to a broad range
of acute and chronic infections. In particular, nosocomial lung
infections are associated with high morbidity and mortality in
immunocompromised patients, e.g. after organ transplantation,
severe burn, cancer, HIV infection and neutropenic patients
[1,2]. Infections in this patient population are problematic, partly
due to the immunocompromised status that allows bacteria to
spread systemically and to resist to antibiotics. The classical
antibiotics with antipseudomonal activities include
aminoglycosides, ceftazidime and carbapenems. Although
carbapenems have been shown to be effective in nosocomial
pneumonia and are currently the most prescribed antibiotics,
15% of P. aeruginosa clinical isolates are resistant to imipenem
[3]. Imipenem has been shown to be associated with frequent
development of drug resistance of P. aeruginosa [4], inducing
the exacerbation of the host inflammatory response, as shown
for ceftazidime [5].
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Its large genome predisposes P. aeruginosa to survive in a
hostile environment. In addition to an array of exo/endotoxins
and enzymatic products that hijack host defense, P. aeruginosa
harbors both chromosomal and/or plasmid encoded antibiotic
resistance genes, limiting antibiotic treatment efficacy [6].
Indeed, it has been established that P. aeruginosa is the most
common multidrug-resistant (MDR) gram-negative pathogen
causing pneumonia in hospitalized patients [7]. Recent reports
includes P. aeruginosa in the group of ESKAPE pathogens
which exhibited resistance to all available drugs [8], even to
colistin [9]. The overall clinical data reveal significant antibiotic
resistance development over the last 15 years. In addition to
the reduction of therapeutic options, antibiotic resistance to P.
aeruginosa has an increasing impact on patient mortality and
hospitalization cost. In fact, studies have highlighted that 67%
of patient mortality was associated with resistant strains [10],
along with a significant increase of median hospital stay and
costs [11].
Therefore, treatment of P. aeruginosa remains a challenge
and a high medical need exists for novel therapeutic
approaches, especially in high risk patient populations. The
increased prevalence of MDR strains has led to the emergence
of new experimental anti-pseudomonas agents besides
antibiotics. Antibody immunotherapy may be a valuable
addition to standard antibiotic therapy against pneumonia.
Nevertheless, only a few groups have reported positive
experimental data using anti-LPS [12], anti-flagella [13] or anti-
PcrV [14,15] antibodies against P. aeruginosa infection with
limited clinical data. Recently, a small phase IIa study of the
fully human IgM antibody Panobacumab was successfully
completed in hospital acquired pneumonia patients, suggesting
a potential therapeutic impact of Panobacumab treatment [16].
Panobacumab is an IgM/κ monoclonal antibody directed
against the LPS O-polysaccharide moiety of P. aeruginosa
serotype IATS O11. It has been recently characterized in vitro
[17] and its safety and efficacy has been demonstrated in mice
[18] and humans [19].
However, the clinical situation differs from the experimental
conditions, e.g. in patients an antibody will always be
administered in combination with antibiotics. So far, no
preclinical evidence for the efficacy of Panobacumab therapy in
models of immunosuppression has been established, yet a
substantial number of ICU patients are immunosuppressed.
Thus, there is a clear need for a proof of concept of the efficacy
of antibody treatment in in vivo mouse models mimicking these
clinical conditions.
Here, we investigate the efficacy of Panobacumab treatment
in various experimental models of P. aeruginosa that mimic
clinical settings encountered among P. aeruginosa-infected
patients. We study the effect of panobocumab in leukopenic
mice representing a model of neutropenia. We report that
treatment with Panobacumab resulted in enhanced bacterial
clearance with subsequent attenuated lung inflammation in the
context of acute neutropenia. In addition, we studied the effect
of Panobacumab in the presence of Meropenem, a prototypal
antibiotic primarily administered after detection of a P.
aeruginosa infection in a clinical situation. We observe an
additive effect of Panobacumab with Meropenem on bacterial
load and pneumonia as compared to single agent treatment.
Moreover panobacumab-induced reduction of acute




Female C57BL/6 (B6) mice of 10-12 week of age were
obtained from Janvier (Le Genest Saint-Isle, France). All mice
were housed under specific pathogen-free conditions at the
Transgenose Institute (Centre National de la Recherche
Scientifique, Orléans, France) and had access to food and
water ad libitum.
Ethic statement.  All animal experiments complied with the
French Government’s animal experiment regulations and were
approved by the Ethics Committee for Animal Experimentation
of the CNRS Campus of Orleans (CCO; N° CLE CCO
2011-026).
Reagents
The generation of Panobacumab was previously described
[13]. Panobacumab for injection was supplied as sterile, non-
pyrogenic, phosphate-buffered saline (PBS) solution at a
concentration of 312 µg/mL manufactured under GMP (Good
Manufacturing Practice) condition (Kenta Biotech AG,
Schlieren, Switzerland). The control antibody specific for P.
aeruginosa serotype IATS-O1 was generated through the
same technology (manuscript in preparation) and purified MAb
was supplied by Kenta Biotech. Mice were injected
intravenously with 0.4 mg/kg of Panobacumab in 200 µL of
PBS, 4 h after infection. Control animals received PBS.
Meropenem was obtained from the pharmacy and
reconstituted in saline at the concentration of 50 mg/mL.
Aliquots of 1 ml were stored at -20°C and working solutions
were prepared in isotonic saline. Mice were injected
intraperitonealy with 30, 100 or 300 mg/kg in 200 µL of PBS, 2
hours after infection. Control animals received PBS.
Bacterial strains
P. aeruginosa strains 2310.55 and 84, both serotype IATS
O11, were provided by Kenta Biotech with certified titre and
purity. Strain 2310.55 is a highly virulent clinical isolate from an
urinary tract-infected patient, whereas strain 84 is a
Meropenem resistant clinical isolate from a pneumonia patient
(kind gift from Dr. Francois, Bruno, University of Limoges,
France). Strain 84 was classified as Meropenem- resistant by
disk diffusion assay (BD Sensi Disc 231704, Meropenem 10
mg). Uniformity of both strains was confirmed by plating on
brain heart infusion (BHI) agar plates.
Experimental model of neutropenia and Pseudomonas
aeruginosa lung infection
For infections, an overnight culture in 10 mL BHI medium
was prepared, starting from the frozen stock at 37°C and
shaking at 150 rpm. 2.5mL of this culture was taken to start a
fresh culture in 10 mL BHI. The culture was stopped when an
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OD of about 0.4 was reached (corresponding to a bacterial
concentration of about 2x108 bacteria/mL). The bacteria were
washed once in PBS and diluted in saline to obtain a
concentration of 106 bacteria/40 µL. Each inoculum was then
checked for accuracy by plating directly on fresh BHI agar
plates. Mice were anesthetized i.v. with 200 µL with a low dose
of Ketamine / Xylazine (1.25 mg/mL/0.5 mg/mL) and 40 µL of
the bacterial solution or the corresponding vehicle solution
(isotonic saline) was applied intranasally using an ultra fine
pipette tip.
Neutropenia was induced by the intraperitoneal injection of
cyclophosphamide (CP, Sigma) (50, 100, 200 mg/kg) [13] and
evaluated 3, 5 or 7 days after CP injection. Neutropenic mice
were infected with P. aeruginosa, 3 days after CP treatment,
and neutropenic or non-neutropenic were all sacrificed 24 h
after the infection.
Hematologic analysis
Blood was drawn from mice, under anesthesia with
isofluorane (CSP), into tubes containing EDTA (Vacutainer,
Becton Dickinson), following manufacturer’s instructions.
Hematologic parameters were determined using a 5-part-
differential hematology analyzer (MS 9.5, Melet Schloesing
Laboratoires).
Broncho-alveolar lavage and organ sampling
Broncho-alveolar lavage fluid (BALF) was collected 24 h
after P. aeruginosa administration by cannulating the trachea
under deep ketamine/xylazine anaesthesia and washing the
lung twice with 1 mL saline at room temperature. The lavage
fluid was centrifuged at 2000 rpm for 10 min at 4°C and the
supernatant was stored at -80°C for analysis. The cell pellet
was resuspended in PBS, counted in a haemocytometer
chamber and cytospin preparations were made using a
Shandon cytocentrifuge (1000 rpm for 10 min). The cells were
stained with Diff-Quick (Dade Behring, Marburg, Germany) and
counted for neutrophils and macrophages.
Lung bacterial load
Lung total weights were recorded after sacrifice and
expressed as a percentage of body weight. Lung homogenates
were prepared in 2 mL of isotonic saline solution using a
Dispomix tissue homogenizer (Medic Tools). Ten-fold serial
dilutions of homogenates were plated on brain-heart infusion
agar plates (Biovalley). Plates were incubated at 37°C and 5%
CO2, and the numbers of cfu were enumerated after 24 h.
Cytokine determination
IL-6 and IL-1β concentrations in lung homogenates were
measured by ELISA (Duoset Kit; R&D Systems) according to
the manufacturer’s instructions (with detection limits at 50 pg/
mL).
Myeloperoxidase (MPO) activity
Lung homogenates were centrifuged at 10,000 _ g for 10 min
at 4°C and the supernatant was discarded. The pellets were
resuspended in 1 ml of PBS containing 0.5%
hexadecyltrimethyl ammonium bromide (HTAB) and 5 mM
EDTA and then incubated for 2 h at 60°C to inactivate the
endogenous catalases. Following a new centrifugation, 50 µl of
supernatant was placed in test tubes with 200 µl of PBS-HTAB-
EDTA, 1.6 ml of HBSS, 100 µl of o-dianisidine dihydrochloride
(1.25 mg/ml), and 100 µl of 0.05% H2O2 After 15 min of
incubation at 37°C under agitation, the reaction was stopped
with 100 µl of 1% NaN3. The MPO activity was determined as
absorbance at 460 nm against blank (reaction mixture with
saline in place of sample).
Statistical analysis
Statistical evaluation of differences between the
experimental groups was determined by using One-way
ANOVA followed by a Tukey’ post test. All tests were
performed with Graphpad Prism, Version 4.03 for Windows
(GraphPad Software Inc., San Diego California USA,
www.graphpad.com). All data are presented as mean ±
Standard Error of the Mean (SEM). A p value < 0.05 was
considered significant.
Results
P. aeruginosa clinical strain 2310.55, serotype O11
induces acute lung infection in neutropenic mice
Cyclophosphamide (CP), a well-known cytostatic and
immunosuppressant drug, was used to induce neutropenia. We
first established a dose and time dependency of CP in B6 mice
to reduce circulating leukocytes in the blood. Significant and
dose-dependent leucopenia was induced 3 days after i.p.
injection in B6 mice (Figure 1A) with a significant decrease in
the circulating monocytes (Figure 1B), granulocytes (Figure
1C) and lymphocytes (Figure 1D). No significant changes of
body-weight was observed (data not shown) suggesting the
absence of major CP-induced toxicity after a single dose.
Furthermore, maximum neutropenia was observed at 3 days,
and a significant recovery in neutrophil counts was found after
5 and 7 days post CP injection (Figure 1).
Next we established an acute pneumonia infection in
immunocompromised B6 mice with P. aeruginosa for the
evaluation of treatment effects of a single dose of the human
monoclonal anti LPS serotype O11 IgM antibody,
Panobacumab. Therefore, mice were submitted to mild, non-
lethal (105 cfu) and acute (106 cfu) P. aeruginosa lung infection
3 days after CP injection at different doses in B6 mice.
Bacterial load in the lung and lung weight, as a surrogate
marker of pneumonia, were determined 24 h later. We
observed a significant increase in lung bacterial load (Figure
1E) and lung weight (Figure 1F) after 100 mg/kg CP injected
mice as compared to untreated controls, reaching
approximately the same bacterial load in the lungs of untreated
animals after an acute infection with a log higher inocoulum of
106 cfu (Figure 1E and F). An additional increase of about 6-log
in bacterial load was noticed after a treatment with 200 mg/kg
CP, resulting in significant mortality rates (data not shown). In
summary, an infection with P. aeruginosa strain 2310.55 with
an inoculum of 105 cfu 3 days after 100mg/kg CP resulted in a
robust increase of lung weights and bacterial load indicating
Therapy of P. aeruginosa Pneumonia with Antibody
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Figure 1.  Enhanced P. aeruginosa-induced pneumonia in cyclophosphamide immunosuppressed mice.  Myelodepression
by cyclophosphamide causes neutropenia and enhanced pneumonia. Total white blood cells (A), monocytes (B), granulocytes (C)
and lymphocytes (D) were determined. B6 mice received intra-peritoneal injection of 200 µL of cyclophosphamide at 50, 100 and
200 mg/kg and the hematogram was analyzed at 3, 5 and 7 days. Separate groups of mice were infected 3 days after CP injection
by intra-nasal instillation of 40 µL of P. aeruginosa strain 2310.55 (105 or 106 cfu). Lung cfu (A) and lung weight (B) were recorded
24 h after infection. Groups of 7 mice were used and mean values ± SEM are shown (One-way ANOVA with Tukey’s Multiple
Comparison Test; * p<0.05, ** p<0.01, *** p<0.001). The results are representative of three independent experiments.
doi: 10.1371/journal.pone.0073396.g001
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uncontrolled pneumonia. Therefore, these experimental
parameters were chosen for the evaluation of the therapeutic
Panobacumab efficacy.
Therapeutic and specific effect of Panobacumab on P.
aeruginosa infection in neutropenic mice
As previously demonstrated, passive immunization of
animals with Panobacumab enhanced survival of animals after
P. aeruginosa infection, reduced bacterial dissemination [17]
and lung weight including pro-inflammatory cytokines and
histological lesions in immunocompetent mice [18]. Since
exacerbation of pneumonia is frequently observed in
neutropenic patients, we tested in the animal model of
neutropenia whether Panobacumab has a beneficial effect on
P. aeruginosa-induced pneumonia by analyzing the bacterial
load and lung weight as measure of lung inflammation. As
expected, in immunocompetent mice, treatment of infected
mice with 0.4 mg/kg Panobacumab resulted in significant
decrease in bacterial load (Figure 2A) of about 1.2 cfu (log10)
and lung weight (Figure 2B). Importantly, in animals with
severely impaired immune system due to CP treatment,
therapeutic treatment with a single dose of 0.4 mg/kg
Panobacumab resulted in a comparable and significant
reduction of bacterial load (Figure 2A) of and lung weight
(Figure 2B) as compared to mice not treated with the antibody.
We observed that upon CP treatment and after infection,
inflammatory cell recruitment in BALF was greatly reduced
(Figure 3A), reaching 90% diminution for neutrophils (Figure
3B), which is consistent with the systemic leucopenia we
described in Figure 1; in which we do not observe any effect of
Panobacumab on the recruited cell number. As we
demonstrated a significant effect of Panobacumab treatment in
bacterial clearance after infection (Figure 2), we investigated
more specifically neutrophil recruitment in the lungs. Upon
infection, in the immunosuppressed animals, Panobacumab
induced a reduced neutrophil recruitment, as determined by
MPO measurement, as a surrogate marker of neutrophil
recruitment, in the lungs (Figure 3C). Inflammation is essential
for host defense but can cause tissue damage and organ
failure if exaggerated and protracted. Therefore we
investigated the effect of local levels of inflammatory mediators
upon P. aeruginosa infection in lung homogenates 24 h post-
infection in immuno-compromised hosts. The pro-inflammatory
cytokines IL-6 (Figure 3D) and IL-1β (Figure 3E) were
significantly lower, after infection, in the lung compartment of
panobacumab-treated animals as compared to untreated
animals. This was accompanied by a significant survival benefit
(Figure 4). These data clearly indicate that in the context of
immunosuppression, therapeutic administration of
Panobacumab, reduces significantly the production of
inflammatory mediators. Finally, we investigated whether the
protection effect could be mediated by the presence of
nonspecific IgM antibodies e.g. having a broad anti-
inflammatory effect. Therefore we included a monoclonal
human IgM antibody directed against P. aeruginosa
lipopolysaccharide serotype O1 as a control (Ctrl O1 Mab). In
both, the immunocompetent and immunosuppressed context,
no significant effect of the O1-specific antibody was observed
(Figure 2). Collectively, these data demonstrate that a single
dose of monoclonal antibody Panobacumab reduces, in a
serotype specific manner, the bacterial load in the lung of
severely neutropenic animals and thereby decrease
inflammatory responses and pneumonia.
Therapeutic and specific effect of Panobacumab on P.
aeruginosa infection in combination with antibiotic
administration
In the absence of strong adverse effects, current guidelines
recommend the use of combination strategy of two anti-
pseudomonal antibiotics when the local resistance patterns and
patients risk factors suggest the opportunity of P. aeruginosa
pneumonia. Combined therapy is thought to reduce the
emergence of drug resistance [20] and to enhance the
therapeutic due to synergy [21]. In this context, we investigated
the combined effect of Panobacumab with a classical anti-
pseudomonas antibiotic Meropenem.
First, we titrated the amount of Meropenem in an acute
infection with P. aeruginosa strain 2310.55. A dose of 30 mg/kg
was ineffective, whereas doses of 100 and 300 mg/kg induced
a significant reduction in both bacterial load as well as lung
weight (Figure 5A and B). For further experiments in the
combination studies, the dose of 100 mg/kg of Meropenem was
chosen, approximately corresponding to a scale-down of dose
used in humans for 72h of treatment [22]. Meropenem
treatment was started 2 hours and Panobacumab was given 4
hours after the infection. We selected this scenario to model
the clinical situation where antibiotics treatment is generally
started immediately after a suspected pneumonia while a
specific immunotherapy would be initiated at a later time point
after confirmation of a P. aeruginosa infection. Upon infection,
Panobacumab-treated mice exhibited reduced bacterial load
(Figure 5C) and lung weight (Figure 5D) as compared to
untreated or control IgM antibody treated animals. In addition,
Meropenem-treated animals presented a mild attenuation of
lung weight. Nevertheless, the combined treatment of
Meropenem and Panobacumab lead to an additive reduction of
bacterial load and lung weight when compared to single-treated
groups (Figure 5C and D). Therefore the results clearly indicate
a beneficial effect of using Panobacumab in combination with
antibiotics for the treatment of P. aeruginosa pneumonia.
Therapeutic effect of Panobacumab on antibiotic
resistant P. aeruginosa infection
P. aeruginosa is a common multidrug-resistant (MDR) gram-
negative agent causing pneumonia in hospitalized patients [7].
In this context, we investigated the effect of Panobacumab
against a Meropenem-resistant P. aeruginosa strain.
We first validated the Meropenem resistance of strain 84 in
vitro as compared to the classical non-resistant strain 2310.55.
In the presence of 1µg/mL of Meropenem in the culture broth,
strain 2310.55 was unable to grow as compared to strain 84
which grew comparable to the untreated strain 2310.55 (Figure
6A). We then addressed the effect of Panobacumab against an
acute lung infection with P. aeruginosa strain 84. A high dose
of Meropenem (300mg/kg) was given 2 hours after the infection
while Panobacumab treatment started 4 hours after the
Therapy of P. aeruginosa Pneumonia with Antibody
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infection. Upon infection, Panobacumab-treated animals
exhibited a significant decrease of lung bacterial load (Figure
6B) as compared to untreated animals. Meropenem-treated
animals presented a similar slight reduction of lung infection
(about 1log) which heavily diminished compared to the one
observed with the non-resistant P. aeruginosa strain 2310.55
where Meropenem induced a large reduction in both lung
bacterial load (Figure 6C) and lung weight (Figure 6E). In the
context of Meropenem-resistant P. aeruginosa acute lung
infection, the combined treatment of Meropenem and
Panobacumab did not lead to an additive reduction of lung
parameters (Figure 6B and D) as compared to combined
treatment against non-resistant P. aeruginosa strain (Figure 6C
and D). In summary, our results demonstrated a beneficial
effect in treatment of P. aeruginosa pneumonia with
Panobacumab independently of the resistance profile of the
infecting P. aeruginosa strain.
Figure 2.  Therapeutic and specific effect of Panobacumab on P. aeruginosa-induced pneumonia in immunosuppressed
mice.  B6 mice were immunosuppressed with cyclophosphamide (100 mg/kg) and 3 days later infected by intra-nasal instillation of
40 µL of P. aeruginosa strain 2310.55 (2x105 cfu). Panobacumab or a control anti-LPS: O1 IgM MAb (Ctrl O1 MAb, with specificity
to serotype O1) were given i.v. at 0.4 mg/kg, 4 h after the infection. Lung cfu (A) and lung weight (B) were recorded 24 h after the
infection. Groups of 14 mice were used and mean values ± SEM are shown (One-way ANOVA with Tukey’s Multiple Comparison
Test; ns: non significant, * p<0.05, ** p<0.01, *** p<0.001). The results are a pool of two independent experiments.
doi: 10.1371/journal.pone.0073396.g002
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Discussion
Previously we established in immunocompetent animals a
clear benefit for the treatment of P. aeruginosa (serotype O11)
pneumonia with Panobacumab leading to a reduction in
bacterial load in the lungs and enhanced survival benefit [18].
We reported here that therapeutic administration of
Panobacumab protects neutropenic mice from acute
pneumonia. To evaluate the efficacy of this antibody in a
clinical situation mimicking immunocompromised patients, we
first established a model of neutropenia using
cyclophosphamide (CP), a nitrogen alkylating molecule used
as anti-cancerous agent in the clinic [23]. Once injected
intraperitoneally, CP resulted in a 60-95% reduction of
leukocyte numbers depending on the CP dose, including a
massive reduction of granulocytes in whole blood after three
days, indicating a severely immunocompromised state. Using
this model, we showed that CP-treated mice exhibited a high
susceptibility to P. aeruginosa infection associated with severe
pneumonia and increased bacterial load This is in line with
earlier publications reporting enhanced susceptibility to P.
aeruginosa in CP-immunosuppressed mice [24]. Once
established, we investigated the effect of Panobacumab on
bacterial clearance and pneumonia induced by P. aeruginosa
in this immunocompromised mouse model, choosing a regimen
of CP dosing that allowed to achieve a significant immune
suppression without an increase in mortality. We showed that
systemic administration of Panobacumab induced a significant
decrease in lung weight and bacterial load, leading us to the
conclusion that the observed effects were dependent on the
interaction between Panobacumab and O11-LPS from the
infecting P. aeruginosa strain, as no positive effect was noticed
Figure 3.  Reduced lung inflammation after Panobacumab treatment in immunosuppressed P. aeruginosa-infected
mice.  B6 mice were immunosuppressed with cyclophosphamide (100 mg/kg) and 3 days later infected by intra-nasal instillation of
40 µL of P. aeruginosa strain 2310.55 (2x105 cfu). Panobacumab was given i.v. at 0.4 mg/kg, 4 h after the infection. Absolute
numbers of cells (A), neutrophils (B) were measured in BALF 24 h after infection. Lung MPO (C) was recorded 24 h after infection.
The concentrations of IL-6 (D) and IL-1β (E) in lung homogenates were determined 24 h after infection. Groups of 8-10 mice were
used and mean values ± SEM are shown (One-way ANOVA with Tukey’s Multiple Comparison Test: * p<0.05, *** p<0.001). The
results are a pool of two independent experiments.
doi: 10.1371/journal.pone.0073396.g003
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against an O1-LPS strain. In the CP-induced neutropenia
model (100mg/kg), the number of granulocytes was reduced
about 80% as compared to untreated mice, which is similar to
the observed massive leucopenia present in hematopoietic
transplantation recipient [25,26] or HIV patients [27]. Despite
severe immune suppression, the treatment with Panobacumab
resulted in a reduction of bacterial load and inflammation in the
lung, indicating that reduced leukocyte numbers might still be
sufficient to mediate bacterial clearance after opsonization by
Panobacumab. The first immune cells encountering P.
aeruginosa in the lung are alveolar macrophages which can
internalize and eliminate bacterial pathogens. However, their
main functions probably rely on the production of chemokines
and cytokines, which are then responsible for neutrophil
recruitment [28,29]. In fact, depletion of macrophages has been
reported to result in contradictory outcomes regarding bacterial
clearance, suggesting that the presence of very few
macrophages could be sufficient for induction of neutrophil
recruitment [30–32]. Neutrophil recruitment to the lung is a
major component of the protective host immune response
against P. aeruginosa pneumonia, as neutrophil depletion
renders mice highly susceptible to P. aeruginosa infections
[33,34]. We have shown previously that treatment with
Panobacumab led to a massive accumulation of granulocytes
in broncho-alveolar lavage and in the lungs [18]; and the
proposed modes of action include antibody–mediated
opsonophagocytosis and complement activation. Thus
phagocytes, such as granulocytes and macrophages,
constitute an integral part of the mechanism of action of
Panobacumab. As such, a beneficial effect of this treatment in
a situation of profound leucopenia was not readily observed.
Alternatively phagocyte-independent effects, such as
Figure 4.  Enhanced survival after Panobacumab treatment
in immunosuppressed P. aeruginosa-infected mice.  B6
mice were immunosuppressed with cyclophosphamide (100
mg/kg) and 3 days later infected by intra-nasal instillation of 40
µL of P. aeruginosa strain 2310.55 (2x105 cfu). Panobacumab
was given i.v. at 0.4 mg/kg, 4 h after the infection. Survival was
monitored 24 h after infection. Groups of 8-10 mice were used.
doi: 10.1371/journal.pone.0073396.g004
immobilization of bacteria, or complement activation could also
contribute to bacterial clearance in this model. Both effectors
functions have been shown to play a critical role in the activity
of antibodies against bacterial cell surface components,
including antibodies to P. aeruginosa lipopolysaccharide [35].
In addition the reduced lung levels of IL-6, IL-1β as well as
neutrophil influx upon infection under Panobacumab treatment
would indicate that the reduction of the bacterial load by
Panobacumab resulted in an overall attenuated pro-
inflammatory response. Unrestrained up-regulation of the
inflammatory response is associated with exacerbated tissue
injury and severe airway disease.
In the clinic, antibiotics are administered immediately after
confirmation of bacterial infection. Nevertheless, therapeutic
strategies have evolved following a “hit hard and hit fast” rule to
provide an initial and critical adequate therapy, which is
associated with reduced morbidity and mortality. Recent
guidelines for pneumonia management recommended
combined use of anti-pseudomonal agents [36]. Meropenem is
a widely used antibiotic with high activity against most gram-
negative bacteria and it is commonly used in empiric therapies
for infectious diseases [37]. Therefore patients receiving
Panobacumab for the treatment of pneumonia will always
receive antibiotics before the diagnosis of a P. aeruginosa
infection has been established. Thus, in the co-treatment
model described here, mice were treated with Meropenem 2
hours after challenge and after additional 2 hours with
Panobacumab to mimic clinically relevant treatment schedules.
Meropenem and Panobacumab treatments alone resulted in a
reduction of bacterial load and inflammation in the lung, but
Panobacumab had an additive effect in the co-treatment
experiments. Similar effects have been described for a
nontherapeutical treatment with anti-PcrV (Mab166) and
Tobramycin [38]. Nevertheless, as we have administered the
treatment after the infection, we could demonstrate a
therapeutic benefit for the combination of Panobacumab with
Meropenem administration, providing evidence for a new, more
effective therapeutic strategy against P. aeruginosa infections.
Recent reports have established that nosocomial strains of P.
aeruginosa are frequently multi-drug resistant and that their
prevalence is increasing worldwide, especially in high-risk
populations [39,40]. Clinical treatment schedule for suspected
pneumonia always include antibiotics and especially
Meropenem which is the prototypal anti-pseudomonas
antibiotic. Upon pneumonia induced by Meropenem-resistant
P. aeruginosa strain, this treatment should be ineffective and
lead to deteriorated patient condition. In this context of a
diminished host response, such as immunosuppression
induced by cyclophosphamide-treatment, we could
demonstrate here that the therapeutic administration of
Panobacumab therapy significantly reduced lung bacterial load
in mice infected with Meropenem-resistant P. aeruginosa
strain. Surprisingly Meropenem at 300mg/kg still had an effect
as compared to the untreated control group, despite that the
strain was identified in vitro as resistant. In this context it has to
be noted that the virulence of this isolate was significantly
smaller than the sensitive strain 2310.55 used, as seen by the
higher inoculum necessary to establish an infection (107 as
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compared to 106). Therefore it is possible that the addition of a
high dose of Meropenem simply slowed bacterial growth,
resulting in a significant difference in bacterial load after 24
hours compared to untreated animals. Furthermore, the
reduction in bacterial load of approx. 1 log in 24 hours upon
treatment with Panobacumab was in line with results seen with
the Meropenem sensitive strain, and addition of a high dose of
Meropenem in combination with Panobacumab did not improve
the effects, which indicates again that the effect observed was
due to the use of Panobacumab. In conclusion, our study
provides evidence for a beneficial effect of Panobacumab
therapy for P. aeruginosa pneumonia in a model of severe
neutropenia as well as in a combination therapy with
Meropenem. Furthermore Panobacumab therapy also showed
efficacy against one meropenem resistant P. aeruginosa strain,
which is an important step in the light of the fact that most
severe nosocomial infections with P. aeruginosa occur in
immunocompromised patients and that emergence of antibiotic
resistant strain poses a significant risk to standard antibiotic
therapy. Overall the results presented here could open the door
for the inclusion of immunosuppressed patients with resistant
infections in clinical studies of antibody treatment.
Figure 5.  Effect of Panobacumab on P. aeruginosa infection alone and in combination with antibiotic administration.  B6
mice received intra-nasal instillation of 40 µL of P. aeruginosa strain 2310.55 (106 cfu). Meropenem or saline was given ip at 30, 100
and 300 mg/kg, 2 h after the infection. Lung cfu (A) and lung weights (B) were recorded 24 h after the infection. Panobacumab or a
control anti-LPS: O1 IgM MAb (Ctrl O1 MAb, with specificity to serotype O1) were given i.v. at 0.4 mg/kg, 4 h after the infection,
alone or in combination with Meropenem, lung cfu (C) and lung weight (D) and lung cfu (B) were recorded 24 h after the infection.
Groups of 8-25 mice were used and mean values ± SEM are shown (One-way ANOVA with Tukey’s Multiple Comparison Test; ns:
non significant, * p<0.05, ** p<0.01, *** p<0.001). The results are a pool of three independent experiments.
doi: 10.1371/journal.pone.0073396.g005
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Figure 6.  Effect of Panobacumab on Meropenem-resistant P. aeruginosa infection.  After overnight preculture, P. aeruginosa
strain 84 and 2310.55 were grew for 9 h in the presence or not of 1µg/mL of Meropenem. Optical density at 600nm was recorded
over the period (A). B6 mice received intra-nasal instillation of 40 µL of Meropenem-resistant P. aeruginosa strain 84 (107 cfu) (B
and D) or classical strain 2310.55 (106 cfu) (C and E). Meropenem or saline was given ip at 300 mg/kg, 2 h after the infection.
Panobacumab was given i.v. at 0.4 mg/kg, 4 h after the infection, alone or in combination with Meropenem. Lung cfu (B and C) and
lung weights (D and E) were recorded 24 h after the infection. Groups of 7 mice were used and mean values ±SEM are shown
(One-way ANOVA with Tukey’s Multiple Comparison Test; ns: non significant, * p<0.05, ** p<0.01, *** p<0.001). The results are a
pool of two independent experiments.
doi: 10.1371/journal.pone.0073396.g006
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